MedTrace Logo

Cognitive Protection - Dexmedetomidine and Cognitive Reserve

NCT00455143 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2019-07-17

Study results available
· View outcomes & findings →

Summary

This is a pilot study to evaluate the effect of dexmedetomidine in the prevention of delirium in non-cardiac surgical patients. The preliminary data regarding the effect of dexmedetomidine on delirium comes from a study underway at Stanford. We propose to randomize fifty patients into two different protocols, one using dexmedetomidine until PACU discharge (hip replacement) and the other using dexmedetomidine for 24 hours in a monitored setting.

Conditions

  • Postoperative Delirium
  • PD
  • Postoperative Cognitive Dysfunction
  • POCD

Interventions

DRUG

Precedex (Dexmedetomidine)

Dexmedetomidine started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.

DRUG

Placebo

Matching placebo given prior to surgery and continued for 24 hours postoperatively

Sponsors & Collaborators

Principal Investigators

  • Jeff Silverstein, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2009-04-30
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00455143 on ClinicalTrials.gov